Among these, HSP-selective small molecules and biologics (e.g., client-selective HSP90 inhibitors, 9B8 mAb) are attractive because their pharmacology can be finely tuned and monitored, but their success will ultimately depend on achieving joint-restricted exposure to avoid off-target toxicity on ubiquitous HSP networks (e.g., cardiotoxicity, impaired stress tolerance, tumor surveillance). The gene discussed is HSP90AA1; the disease is neoplasm.